NEOPLASMS

This study tests a new drug called E7386 combined with other anticancer drugs in people with advanced solid tumors, including liver, colorectal, and endometrial cancers. The main goals are to check safety and find the best dose. About 300 adults are taking part in this early-phas…

This study tests whether adding the drug dostarlimab to standard chemotherapy helps people with advanced or recurrent endometrial cancer live longer without their cancer getting worse. About 785 participants will receive either dostarlimab plus chemo or a placebo plus chemo. The …

This phase 2 trial tests a treatment called Lete-Cel, which uses a patient's own immune cells that have been specially trained to attack cancer cells. It is for people with advanced synovial sarcoma or myxoid/round cell liposarcoma whose tumors have a specific marker (NY-ESO-1) a…

This study aimed to test an experimental virus therapy (G207) injected directly into the brain tumor, combined with a single dose of radiation, in children whose high-grade glioma had come back after standard treatment. The goal was to see if this approach could help children liv…

This early-phase study tests a new drug called remzistotug, alone or with other cancer treatments, in 152 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. This is a first-in-human trial, so …

This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. It involves 532 adults with stage IIIB, IIIC, or IV disease who cannot have surgery or radiation. Researchers…

This study tests a combination of four drugs (irinotecan, dabrafenib, trametinib, and either cetuximab or panitumumab) as a second treatment option for people with advanced colorectal cancer that has spread and has a specific BRAF gene mutation. The goal is to see if this drug mi…

This program gives patients with advanced ROS1-positive non-small cell lung cancer access to taletrectinib, an experimental drug, when no approved treatments or other clinical trials are available. Participants must be 18 or older, have a confirmed ROS1 gene fusion, and adequate …

This early-stage study tests a new drug called GSK3745417, given alone or with another drug (dostarlimab), in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. This is a…

This study gives people with myelofibrosis continued access to the drug momelotinib, which helps control the disease. It includes 237 participants who were already taking the drug in earlier studies and have not had their disease get worse. The goal is to check long-term safety a…

This early-stage study tests a new experimental drug called GSK6097608, given alone or with other cancer medicines, in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Abo…

This early-stage study tests an experimental drug called dostarlimab (TSR-042) in 730 adults with advanced solid tumors who have run out of standard options. The drug works by helping the immune system attack cancer cells. The study has two parts: first to find the safest dose, t…

This early-stage study tests a new oral drug (GSK4524101) alone and with another drug (niraparib) in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 42 partic…

This study tests whether a combination of two targeted drugs (encorafenib and cetuximab), given alone or with chemotherapy, works better than standard chemotherapy for people with a specific genetic form of advanced colorectal cancer (BRAF V600E mutation) that has spread and hasn…

This early-phase study tests a new experimental drug, BI 765179, in adults with advanced solid tumors or head and neck cancer. The first part finds the safest dose when given alone or with another drug (ezabenlimab). The second part tests it with pembrolizumab in head and neck ca…

This early-stage study tests an experimental pill, ATV-1601, for people with advanced solid tumors or certain breast cancers that have a specific AKT1 gene mutation. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 134 ad…

This study tests if bevacizumab, a drug that blocks blood vessel growth, can help adults with recurrent respiratory papillomatosis (RRP) go longer between surgeries to remove wart-like growths in their airways. About 21 participants who need at least two surgeries per year will r…

This study tests a new treatment using a patient's own immune cells that are genetically modified to better recognize and attack certain solid tumors. It is for people with advanced cancers like synovial sarcoma that have not responded to other treatments. The goal is to see if t…

This study tests a treatment called Lete-Cel, which uses a patient's own immune cells that are specially trained to attack cancer cells. It is for people with advanced synovial sarcoma or myxoid/round cell liposarcoma that has not been treated yet. The main goal is to see if the …

This early-phase study tests a treatment that adds a special antibody to a patient's own immune cells (T cells) to help them find and attack lymphoma cells. The goal is to find a safe dose of these modified cells to give after a stem cell transplant, to try to prevent the cancer …

This study tests a new drug called TSR-022 in people with advanced solid tumors that have not responded to other treatments. The drug is an antibody that targets a protein on immune cells to help fight cancer. The trial has two parts: first, finding the safest dose, and then test…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study tests a new drug called JNJ-63723283 that helps the immune system fight cancer. It is for people with advanced cancers like lung, melanoma, bladder, and others that have not responded to standard treatments. The goal is to find the best dose and see if it can shrink tu…

This early-phase study tests a new treatment for people with certain lymphomas that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in the lab to recognize and attack cancer cells, plus an added navi…

This study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapies. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells carrying a marker…

This study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after the…

This early-stage study tests a new treatment called ACIT-1, which uses donated immune cells to help fight cancer. About 34 adults with pancreatic or other cancers will receive one of four doses to find the safest and most effective dose. The goal is to see if the therapy can safe…

This early-phase study tests whether amivantamab, a drug that targets certain cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different doses to find the sa…

This study tests whether contrast-enhanced mammography (CEM) finds breast cancer more accurately than standard mammography in women who have already had breast cancer. About 1,647 women ages 30-85 will get both types of mammograms to compare detection rates and false alarms. The …

This study aims to create a new way to screen for many types of cancer using just a routine blood test. Researchers will analyze data from 10 million people to train a computer model that can spot signs of cancer. The goal is to develop a low-cost, non-invasive tool that could be…

This study tests a 7-week group program led by trained peers (not doctors) to help cancer survivors recently finished with curative treatment manage anxiety and depression. 234 participants from Denmark join weekly sessions to build skills in self-managing emotional symptoms. The…

This study looks at whether a remote, partner-based strength training program is practical and helpful for Hispanic prostate cancer survivors and their unpaid caregivers. About 58 pairs will take part in 3 months of supervised group exercise classes via video, with a 3-month foll…

This study reviews existing medical records to understand how blood clots are managed in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are tested—this …

This study tests if a small, wearable patch called TempTraq can detect fevers earlier than standard checks in cancer patients receiving immunotherapy. Early detection of fever may help prevent severe cytokine release syndrome (CRS), a serious side effect. About 136 adults with ca…

This study tests a modified clinical program to help doctors better prevent blood clots (VTE) in cancer patients starting treatment. About 25 patients and their doctors will take part. The program includes education for doctors and a structured risk assessment to decide if blood-…

This study looks back at the medical records of 232 adults with cancer who took the immunotherapy drug M7824. The goal is to make a complete list of all side effects caused by the drug. By understanding these side effects, doctors hope to prevent or reduce them in future cancer t…

This study tests a program called Potlako+ that includes community education, help for healthcare workers, and patient guides to see if it helps people with cancer symptoms get diagnosed and treated faster. About 874 adults in Botswana, including those with HIV or cancer symptoms…

This study looks at whether educating doctors in small and mid-sized city hospitals about official guidelines can improve how they test and treat patients with advanced lung cancer. About 1000 patients with metastatic non-small cell lung cancer will have their medical records rev…

This study provides standard cancer care to patients at the National Cancer Institute while collecting their medical information for research. It is open to adults and children with cancer or HIV, including those with rare diseases or who cannot get proper care elsewhere. The goa…

This study follows 500 children with growth hormone deficiency who are taking somapacitan (a once-weekly injection) as part of their normal medical care. Researchers will track side effects, medication errors, and new cases of cancer or type 2 diabetes over 10 years. The goal is …

This study is watching how a robotic tool called the Ion Endoluminal System performs when doctors use it to take samples from lung spots or guide treatment. About 1,300 adults who need a lung biopsy or localization will take part. The goal is to see how often the system correctly…

This study tests a new technology that adjusts the radiation beam in real time to follow lung tumors as they move with breathing. About 20 adults with early-stage lung cancer or limited lung metastases will receive standard radiotherapy with this tracking system. The main goal is…

This study follows 120 people with different cancers (like leukemia, lymphoma, and solid tumors) who already received treatment in an earlier study. The main goal is to track serious side effects and other health issues over time. No new treatment is given—just ongoing safety mon…